For subscribers
Singapore well placed for investments in new drugs, says pharma giant MSD
Sign up now: Get ST's newsletters delivered to your inbox
The concept of using mRNA as a medicine had been in the works for as long as 20 years before Covid struck.
PHOTO: © BIONTECH SE 2022
Follow topic:
SINGAPORE - Singapore is set to receive its due share of the deluge of investments flowing into the research and development of new drugs, including mRNA-based vaccines and therapies.
While mRNA vaccines have earned validation through coronavirus jabs, the future of the breakthrough technology they represent goes beyond Covid-19 itself, said Singapore-based David Peacock, who was appointed last month as the Asia-Pacific president of MSD, the international trade name of American pharma giant Merck & Co.
